The National Health Research Institutes (NHRI) has developed a combination chemotherapy regimen to treat pancreatic cancer that reduces the side effects and extends survival to nearly a year, it said yesterday.
An institute research team’s phase 1 and 2 clinical trials on a chemotherapy regimen of S-1, leucovorin, oxaliplatin and gemcitabine (SLOG) showed promising efficacy and safety in treating patients with metastatic pancreatic ductal adenocarcinoma (PDAC), National Institute of Cancer Research associate investigator Chiang Nai-jung (姜乃榕) said.
PDAC is a highly fatal disease, and as pancreatic cancers often do not show symptoms early in their onset, they are often only detected after they have grown large or spread outside the pancreas, meaning that 80 to 85 percent of patients are in the advanced stages of the disease at their time of diagnosis, Chiang said.
Photo: Lin Hui-chin, Taipei Times
The overall five-year survival rate of PDAC is lower than 5 percent, and systemic chemotherapy is the standard treatment for patients with unresectable advanced or metastatic pancreatic cancer, she said.
The median overall survival of patients with metastatic pancreatic cancer who received first-line gemcitabine monotherapy is three to six months, but newer combination chemotherapy regimens — such as folinic acid (also known as leucovorin), fluorouracil, irinotecan and oxaliplatin (FOLFIRINOX), and nab-paclitaxel plus gemcitabine (AG) — extended the median overall survival to about eight-and-a-half to 11 months, Chiang said.
Although FOLFIRINOX and AG are more effective than monotherapy, they are associated with a higher degree of hematological toxicity and neutropenia, especially in Asians, she said, adding that their team tried to find other regimens better suited for Asian patients.
Some patients are less willing to tolerate the side effects of chemotherapy, but reducing the chemotherapy dosage might also reduce its efficacy, so the institute has been pursuing better solutions for several years, National Institute of Cancer Research deputy director Liu Ko-jiunn (劉柯俊) said.
The researchers spent four years coming up with the SLOG regimen — a fixed-rate infusion (10mg/m2 per minute) of 800mg/m2 of gemcitabine, followed by 85mg/m2 of oxaliplatin once per two weeks, and an oral dosage of S-1 and 20mg/m2 of leucovorin twice per day in the first seven days of a two-week cycle, Chiang said, adding that it can be used as a first-line treatment for PDAC.
With assistance from the Taiwan Cooperative Oncology Group, National Cheng Kung University Hospital, National Taiwan University Hospital, Linkou Chang Gung Memorial Hospital and Kaohsiung Medical University Chung-Ho Memorial Hospital, a total of 73 patients participated in the two phases of clinical trials.
Researchers found that the median overall survival of patients on the SLOG regimen was 11.4 months, the tumor shrinkage rate was above 30 percent, and the gastrointestinal side effects and rates of neutropenia were also reduced, Chiang said.
The biweekly treatment is a feasible regimen with promising effects and safety for patients with advanced PDAC, and it has been included in the clinical practice guidelines in several hospitals, she said.
The researchers are conducting a randomized phase 2 clinical trial comparing SLOG with a modified FOLFIRINOX regimen in patients with advanced pancreatic cancer, Chiang said.
The team’s research was published in the European Journal of Cancer last month.
Thirty-five earthquakes have exceeded 5.5 on the Richter scale so far this year, the most in 14 years, the Central Weather Administration (CWA) said on Facebook on Thursday. A large earthquake in Hualien County on April 3 released five times as much the energy as the 921 Earthquake on Sept. 21, 1999, the agency said in its latest earthquake report for this year. Hualien County has had the most national earthquake alerts so far this year at 64, with Yilan County second with 23 and Changhua County third with nine, the agency said. The April 3 earthquake was what caused the increase in
INTIMIDATION: In addition to the likely military drills near Taiwan, China has also been waging a disinformation campaign to sow division between Taiwan and the US Beijing is poised to encircle Taiwan proper in military exercise “Joint Sword-2024C,” starting today or tomorrow, as President William Lai (賴清德) returns from his visit to diplomatic allies in the Pacific, a national security official said yesterday. Commenting on condition of anonymity, the official said that multiple intelligence sources showed that China is “highly likely” to launch new drills around Taiwan. Although the drills’ scale is unknown, there is little doubt that they are part of the military activities China initiated before Lai’s departure, they said. Beijing at the same time is conducting information warfare by fanning skepticism of the US and
DEFENSE: This month’s shipment of 38 modern M1A2T tanks would begin to replace the US-made M60A3 and indigenous CM11 tanks, whose designs date to the 1980s The M1A2T tanks that Taiwan expects to take delivery of later this month are to spark a “qualitative leap” in the operational capabilities of the nation’s armored forces, a retired general told the Liberty Times (sister paper of the Taipei Times) in an interview published yesterday. On Tuesday, the army in a statement said it anticipates receiving the first batch of 38 M1A2T Abrams main battle tanks from the US, out of 108 tanks ordered, in the coming weeks. The M1 Abrams main battle tank is a generation ahead of the Taiwanese army’s US-made M60A3 and indigenously developed CM11 tanks, which have
Chinese President Xi Jinping (習近平) is unlikely to attempt an invasion of Taiwan during US president-elect Donald Trump’s time in office, Taiwanese and foreign academics said on Friday. Trump is set to begin his second term early next year. Xi’s ambition to establish China as a “true world power” has intensified over the years, but he would not initiate an invasion of Taiwan “in the near future,” as his top priority is to maintain the regime and his power, not unification, Tokyo Woman’s Christian University distinguished visiting professor and contemporary Chinese politics expert Akio Takahara said. Takahara made the comment at a
RSS